Suppr超能文献

他达拉非联合米拉贝隆治疗单药使用他达拉非后仍存在持续性储尿期症状的良性前列腺增生症患者的疗效:一项前瞻性、多中心、开放标签研究

Efficacy of Combination Treatment with Tadalafil and Mirabegron in Patients with Benign Prostatic Hyperplasia Who Presented with Persistent Storage Symptoms After Tadalafil Monotreatment: A Prospective, Multicenter, Open-Labeled Study.

作者信息

Honda Masashi, Kimura Yusuke, Teraoka Shogo, Kawamoto Bunya, Morizane Shuichi, Hikita Katsuya, Takenaka Atsushi

机构信息

Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8503, Japan.

出版信息

Yonago Acta Med. 2022 Aug 4;65(3):231-237. doi: 10.33160/yam.2022.08.009. eCollection 2022 Aug.

Abstract

BACKGROUND

The aim of this study is to evaluate the efficacy and safety of tadalafil, a phosphodiesterase type 5 inhibitor, plus mirabegron, a β-adrenoreceptor agonist, in patients with benign prostatic hyperplasia who presented with persistent storage symptoms after tadalafil monotreatment.

METHODS

The registration of this study started in August 2016 and ended in July 2019. The inclusion criteria included patients aged ≥ 50 years who were diagnosed with benign prostatic hyperplasia and who presented with overactive bladder symptoms. Patients were treated with oral tadalafil 5 mg once daily for 4 weeks. Then, its efficacy was evaluated. Patients who responded to the treatment received oral tadalafil 5 mg once daily for 4 more weeks (monotreatment group). Meanwhile, those who did not respond received oral tadalafil 5 mg and mirabegron 50 mg, which is an add-on treatment, once daily for 4 more weeks (combination therapy group).

RESULTS

After 8 weeks, the monotreatment group (n = 19) and the combination group (n = 56) had significantly better total Overactive Bladder Symptom Score and International Prostate Symptom Score and International Prostate Symptom Score voiding and storage subscale scores. Moreover, the two groups experienced significant improvements in the total Overactive Bladder Questionnaire and Nocturia Quality of Life Questionnaire scores, and Nocturia Quality of Life Questionnaire Bother/Concern subscale score after 8 weeks. However, there were no cases of urinary retention or serious adverse events.

CONCLUSION

Combination treatment with tadalafil and mirabegron is effective and safe for patients with benign prostatic hyperplasia who presented with persistent storage symptoms after tadalafil monotreatment. Hence, tadalafil plus mirabegron is a promising therapeutic option, and it can improve overactive bladder related-quality of life.

摘要

背景

本研究旨在评估5型磷酸二酯酶抑制剂他达拉非联合β肾上腺素能受体激动剂米拉贝隆,对他达拉非单药治疗后仍有持续性储尿症状的良性前列腺增生患者的疗效和安全性。

方法

本研究于2016年8月开始注册,2019年7月结束。纳入标准包括年龄≥50岁、被诊断为良性前列腺增生且有膀胱过度活动症症状的患者。患者口服他达拉非5毫克,每日一次,持续4周。然后评估其疗效。对治疗有反应的患者再口服他达拉非5毫克,每日一次,持续4周(单药治疗组)。同时,无反应的患者口服他达拉非5毫克和米拉贝隆50毫克(联合治疗组),每日一次,持续4周。

结果

8周后,单药治疗组(n = 19)和联合治疗组(n = 56)的膀胱过度活动症总症状评分、国际前列腺症状评分以及国际前列腺症状评分排尿和储尿子量表评分均显著改善。此外,两组在8周后的膀胱过度活动症问卷总分、夜尿生活质量问卷评分以及夜尿生活质量问卷困扰/担忧子量表评分均有显著改善。然而,未出现尿潴留或严重不良事件病例。

结论

对于他达拉非单药治疗后仍有持续性储尿症状的良性前列腺增生患者,他达拉非与米拉贝隆联合治疗有效且安全。因此,他达拉非加米拉贝隆是一种有前景的治疗选择,可改善膀胱过度活动症相关生活质量。

相似文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验